



FOR IMMEDIATE RELEASE

CONTACT:

Karen Wills
Executive Director, Global Marketing
(508) 808-9825
media.inquiries@celerion.com

Celerion Celebrates a Decade of Translating Science Into Medicine

A rich history of providing early clinical research services to the pharmaceutical industry has proven Celerion a leader in helping bring new drugs to market.

Lincoln, Neb., March 10, 2020 (Business Wire) — In March, [Celerion](#) celebrates 10 years of industry leadership providing early clinical research services to the biopharmaceutical industry's most innovative companies. With corporate offices in Lincoln, Celerion's second decade of growth will continue from locations spanning North America, Europe, and Asia.

"We've achieved global recognition as the premier provider of early stage clinical research, building upon the 50-year legacy of our predecessor, Harris Laboratories," said [Susan Thornton, Ph.D.](#), Celerion's chief executive officer. "Our enduring mission is to help customers make rapid, informed decisions to progress new drugs from early development through to market approval. Our name, Celerion, is derived from the Latin word *celeritas*, for swiftness and speed."

Key factors in the company's success have been its strong scientific foundation and demonstrated capabilities in the drug development process, she noted.

-more-

“Translating science to medicine is one of our strengths. While many organizations have broadly expanded services, Celerion has chosen to focus resources on early clinical development to proof of concept. We have made it a priority to access the knowledge, talent, and technology to build the competencies to execute successfully in this space. Investment in these areas has enabled Celerion to partner with our customers to achieve their drug development goals. In 2019, regulatory bodies approved 48 new drugs; Celerion conducted 32 studies with 11 of those drugs. This impressive track record demonstrates our overriding goal of advancing new drugs to market to help those in need of innovative drug therapies.”

Thornton likewise sees Celerion’s success as a byproduct of strong collaborative relationships with leading biopharmaceutical companies throughout the world.

“Over the coming decade, we will continue to embrace the evolving challenges of drug development, working closely with our customers in the hunt for new and better medicines,” said Thornton.

For more information about Celerion’s expertise and their full range of clinical research services, visit www.celerion.com.

About Celerion

[Celerion](http://www.celerion.com), a global leader in early clinical research services, offers a unique combination of medical expertise, clinical operations experience, and scientific excellence that gives its clients the confidence to make fast, accurate decisions about their drug development path. For 50 years, Celerion has leveraged the latest operational concepts and technologies to execute safety/tolerability, pharmacokinetic, and pharmacodynamics studies in highly controlled clinical environments. These include first-in-human dose escalation, drug-drug interaction, cardiac safety, bioequivalence and bioavailability, metabolism and excretion studies, as well as pharmacokinetic evaluations in patients with impaired renal or hepatic function. Celerion offers feasibility, data management, biostatistics, clinical monitoring, and bioanalytical services. Our founding mission is to help our clients get their drugs to market quickly so that they touch the lives of our families, friends, and people in need around the world. For more information, please visit www.celerion.com.

###